Soluble Aβ homeostasis in AD and DS: impairment of anti-amyloidogenic protection by lipoproteins
Explore this paper's citation graph
Summary
The hypothesis that functionally declined lipoproteins may be major determinants in the production of metabolic conditions leading to higher levels of sAβ species and cerebral amyloidosis supports the hypothesis that functionally declined lipoproteins may be major determinants in the production of metabolic conditions leading to higher levels of sAβ species and cerebral amyloidosis.
- Type
- article
- Published
- 2004-08-01
- Cited by
- 34
- References
- 40
- OpenAlex
- https://openalex.org/W15212837
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:27037859
Keywords
Geography
References
- Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease.
- Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons
- Apolipoprotein J and Alzheimer's amyloid beta solubility.
- “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician
- An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.
- Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.
- Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging.
- Detection of apolipoprotein E/dimeric soluble amyloid beta complexes in Alzheimer's disease brain supernatants.
- Water-soluble A(N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains (*)
- Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline.
- Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease.
- Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation.
- Production of the Alzheimer amyloid beta protein by normal proteolytic processing.
- Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome
- Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins.
- Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid.
- Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate.
- Long amyloid beta-protein secreted from wild-type human neuroblastoma IMR-32 cells.
- Lipoprotein‐free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome
- Presence of soluble amyloid β–peptide precedes amyloid plaque formation in Down's syndrome
Cited by
- Plasma Amyloid-β as a Function of Age, Level of Intellectual Disability, and Presence of Dementia in Down Syndrome
- Several Direct and Calculated Biomarkers from the Amyloid-β Pool in Blood are Associated with an Increased Likelihood of Suffering from Mild Cognitive Impairment
- Reliable Measurements of the β-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD
- Antibody‐based approaches in Alzheimer’s research: safety, pharmacokinetics, metabolism, and analytical tools
- Lipid peroxidation and Alzheimer's disease : Key role of Amyloid-β
- Depletion of Vitamin E Increases Amyloid β Accumulation by Decreasing Its Clearances from Brain and Blood in a Mouse Model of Alzheimer Disease*
- Dissociation of β‐amyloid from lipoprotein in cerebrospinal fluid from Alzheimer's disease accelerates β‐amyloid‐42 assembly
- Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer's disease by accelerating the clearance of amyloid-beta.
- Alzheimer's Disease: Focus on the Neuroprotective Role of Melatonin
- Effect of Apolipoprotein E Genotype and Diet on Apolipoprotein E Lipidation and Amyloid Peptides
- Melatonin: A Potential Anti-Oxidant Therapeutic Agent for Mitochondrial Dysfunctions and Related Disorders.
- Preferential Interactions between ApoE-containing Lipoproteins and Aβ Revealed by a Detection Method that Combines Size Exclusion Chromatography with Non-Reducing Gel-shift
- Regulation of apolipoprotein E secretion, lipidation and recycling in the central nervous system
- Mitochondrial therapeutic interventions in Alzheimer's disease.
- Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
- Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta‐analyses
- Differential Roles of Plasma Protein Corona on Immune Cell Association and Cytokine Secretion of Oligomeric and Fibrillar Beta-Amyloid
- The differential effects of fatty acids on enterocytic abundance of amyloid-beta
- Cognitive Deficits in Type-1 Diabetes: Aspects of Glucose, Cerebrovascular and Amyloid Involvement
- Synthesis of human amyloid restricted to liver results in an Alzheimer disease–like neurodegenerative phenotype
Related papers
No related papers recorded.